Drugs / AMG 404
AMG 404
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04885998 | Sep 2021 → Jul 2023 | small cell lung carcinoma | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT04727554 | Apr 2021 → Jun 2023 | cancer | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT04524455 | Oct 2020 → Jan 2023 | acute lymphoblastic leukemia | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT04185883 | Dec 2019 → Dec 2026 expected | cancer | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03853109 | Mar 2019 → Jul 2022 | cancer | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT03296696 | Apr 2018 → Jul 2021 | malignant glioma | Amgen | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04631601 | Jan 2021 → Oct 2023 | prostate carcinoma | Amgen | Terminated | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04524455 ↗ |
| Known as | 20C1.009 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594522 ↗ |
| Known as | Zeluvalimab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594522 ↗ |
| Action | Inhibit | “inhibits its engagement with ligands” NCT03853109 ↗ |
| Modality | Monoclonal antibody | “a monoclonal antibody that binds to PD-1” NCT03853109 ↗ |
| Route | Intravenous | “AMG 404 administered as an IV infusion.” NCT04185883 ↗ |